TNFRSF9 and autoimmune disease: The use of antibodies to target the CD137-CD137L axis is appealing; however, while anti-CD137 antibodies are protective in some models of autoimmune diseases due to activation of Tregs, they can also enhance CD8+ T cell killing activity in the absence of Tregs.